Agenus (AGEN) revenue breakdown
By product, Non-cash royalties is the largest at 95% of fiscal 2025 revenue, growing 30% a year over 7 years.
By region, United States is the largest at 99% of fiscal 2025 revenue, growing 21% a year over 9 years.
Revenue by product
Fiscal years, as Agenus reports them in its 10-K filings; fiscal 2025 total $114M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalties | — | — | $17M | $30M | — | $44M | $45M | $115M | $101M | $109M | 95% |
| Pre-Commercial Product Revenue | — | — | — | — | — | — | — | — | — | $4M | 4% |
| Other services | — | — | — | — | $5M | $7M | $11M | $3M | $2M | $1M | 1% |
| Clinical product revenue | — | — | — | — | — | $587,000 | $762,000 | $116,000 | $482,000 | $334,000 | 0% |
| License fees and milestones | — | — | — | — | — | — | — | $25M | — | — | — |
| Recognition of deferred research and development revenue | — | — | — | — | — | — | — | $12M | — | — | — |
| Research and development services | — | — | — | — | — | — | — | $1M | — | — | — |
| Non-cash royalties and milestones | — | — | — | — | $48M | — | — | — | — | — | — |
| Royalty sales milestone | — | — | — | — | — | — | $25M | — | — | — | — |
| License and collaboration milestones | $2M | $25M | — | — | — | — | — | — | — | — | — |
| Royalty sales milestone | — | — | — | $15M | — | — | — | — | — | — | — |
| Research and development services | $17M | $15M | — | — | — | — | — | — | — | — | — |
| License and collaboration milestones | — | — | $14M | — | — | — | — | — | — | — | — |
| Recognition of deferred research and development revenue | — | — | — | $23M | $12M | $22M | $10M | — | — | — | — |
| License fees and milestones | — | — | — | $76M | $23M | $220M | $5M | — | — | — | — |
| Research and development services | — | — | $4M | — | — | — | — | — | — | — | — |
| Manufacturing services | — | — | — | $3M | — | — | — | — | — | — | — |
| Recognition of Deferred Research and Development Revenue | $4M | $3M | — | — | — | — | — | — | — | — | — |
| Research and development services | — | — | — | $2M | $754,000 | $1M | $2M | — | — | — | — |
| Recognition of Deferred Research and Development Revenue | — | — | $1M | — | — | — | — | — | — | — | — |
| Recognition of Deferred Grant Revenue | — | — | — | — | — | $184,000 | — | — | — | — | — |
| Grant Revenue | — | $168,000 | — | — | — | — | — | — | — | — | — |
| Service revenue | $147,000 | — | — | — | — | — | — | — | — | — | — |
| Recognition of Deferred Grant Revenue | — | — | — | $1M | $91,000 | — | — | — | — | — | — |
| Grant Revenue | $39,000 | — | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Agenus reports them in its 10-K filings; fiscal 2025 total $114M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $20M | $39M | $33M | $149M | $84M | $289M | $88M | $153M | $101M | $113M | 99% |
| Rest of World | $2M | $4M | $4M | $690,000 | $5M | $7M | $11M | $3M | $2M | $1M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AGEN.
Open AGEN in InvestinglyQuestions
Where does Agenus make its money?
In fiscal 2025, by product: Non-cash royalties $109M, Pre-Commercial Product Revenue $4M, Other services $1M, Clinical product revenue $334,000.
From Agenus's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.